Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Slowly progressive invasive rhino-orbito-cerebral aspergillosis: case report and literature review.

de Martin Truzzi G, Furlan Pauna H, Moreira Hazboun I, Benedick Coimbra I, Sakuma ET, Barreto IS, Chone CT, Sakano E.

Clin Case Rep. 2017 Jan 26;5(3):218-224. doi: 10.1002/ccr3.798. eCollection 2017 Mar.

2.

Serum galactomannan index for early prediction of mortality in immunocompromised children with invasive pulmonary aspergillosis.

Han SB, Kim SK, Lee JW, Yoon JS, Chung NG, Cho B, Jeong DC, Kang JH, Kim HK, Lee DG, Lee HS, Im SA.

BMC Infect Dis. 2015 Jul 14;15:271. doi: 10.1186/s12879-015-1014-9.

3.

Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis.

Neofytos D, Railkar R, Mullane KM, Fredricks DN, Granwehr B, Marr KA, Almyroudis NG, Kontoyiannis DP, Maertens J, Fox R, Douglas C, Iannone R, Kauh E, Shire N.

PLoS One. 2015 Jun 24;10(6):e0129022. doi: 10.1371/journal.pone.0129022. eCollection 2015.

4.

Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.

Al-Nakeeb Z, Petraitis V, Goodwin J, Petraitiene R, Walsh TJ, Hope WW.

Antimicrob Agents Chemother. 2015 May;59(5):2735-45. doi: 10.1128/AAC.04723-14. Epub 2015 Feb 23.

5.

Invasive fungal infections in transplant recipients.

Vazquez JA, Miceli MH, Alangaden G.

Ther Adv Infect Dis. 2013 Jun;1(3):85-105. doi: 10.1177/2049936113491936. Review.

6.

Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome.

Barton RC.

Scientifica (Cairo). 2013;2013:459405. doi: 10.1155/2013/459405. Epub 2013 Jan 14. Review.

7.

Eradication of pulmonary aspergillosis in an adolescent patient undergoing three allogeneic stem cell transplantations for acute lymphoblastic leukemia.

Döring M, Zierl A, Mezger M, Lang P, Handgretinger R, Müller I.

Case Rep Transplant. 2012;2012:672923. doi: 10.1155/2012/672923. Epub 2012 Aug 30.

8.

Prognosis of invasive pulmonary aspergillosis in patients with hematologic diseases in Korea.

Kwon JC, Kim SH, Park SH, Choi SM, Lee DG, Choi JH, Yoo JH, Kim YJ, Lee S, Kim HJ, Lee JW, Min WS.

Tuberc Respir Dis (Seoul). 2012 Mar;72(3):284-92. doi: 10.4046/trd.2012.72.3.284. Epub 2012 Mar 31.

9.

Have novel serum markers supplanted tissue diagnosis for invasive fungal infections in acute leukemia and transplantation?

Wingard JR.

Best Pract Res Clin Haematol. 2012 Dec;25(4):487-91. doi: 10.1016/j.beha.2012.10.013. Epub 2012 Oct 23. Review.

10.

Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis.

Chai LY, Kullberg BJ, Johnson EM, Teerenstra S, Khin LW, Vonk AG, Maertens J, Lortholary O, Donnelly PJ, Schlamm HT, Troke PF, Netea MG, Herbrecht R.

J Clin Microbiol. 2012 Jul;50(7):2330-6. doi: 10.1128/JCM.06513-11. Epub 2012 May 2.

11.

Baseline platelet count and creatinine clearance rate predict the outcome of neutropenia-related invasive aspergillosis.

Nouér SA, Nucci M, Kumar NS, Grazziutti M, Restrepo A, Anaissie E.

Clin Infect Dis. 2012 Jun;54(12):e173-83. doi: 10.1093/cid/cis298. Epub 2012 Mar 15.

12.

Real-time nucleic acid sequence-based amplification to predict the clinical outcome of invasive aspergillosis.

Kim SH, Park C, Kwon EY, Shin NY, Kwon JC, Park SH, Choi SM, Lee DG, Choi JH, Yoo JH.

J Korean Med Sci. 2012 Jan;27(1):10-5. doi: 10.3346/jkms.2012.27.1.10. Epub 2011 Dec 19.

13.

Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients.

Bergeron A, Porcher R, Menotti J, Poirot JL, Chagnon K, Vekhoff A, Cornet M, Isnard F, Raffoux E, Brethon B, Lacroix C, Touratier S, Latgé JP, Bouges-Michel C, Tazi A, Derouin F, Ribaud P, Sulahian A.

J Clin Microbiol. 2012 Mar;50(3):823-30. doi: 10.1128/JCM.00750-11. Epub 2011 Dec 14.

14.

Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition.

Nouér SA, Nucci M, Kumar NS, Grazziutti M, Barlogie B, Anaissie E.

Clin Infect Dis. 2011 Oct;53(7):671-6. doi: 10.1093/cid/cir441. Epub 2011 Aug 16.

15.

The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy.

Hope WW, Petraitis V, Petraitiene R, Aghamolla T, Bacher J, Walsh TJ.

Antimicrob Agents Chemother. 2010 Nov;54(11):4879-86. doi: 10.1128/AAC.00673-10. Epub 2010 Aug 16.

16.

Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications.

Sherif R, Segal BH.

Curr Opin Pulm Med. 2010 May;16(3):242-50. doi: 10.1097/MCP.0b013e328337d6de. Review.

17.

Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis.

Koo S, Bryar JM, Baden LR, Marty FM.

J Clin Microbiol. 2010 Apr;48(4):1255-60. doi: 10.1128/JCM.02281-09. Epub 2010 Feb 10. Erratum in: J Clin Microbiol. 2010 May;48(5):1994.

18.

Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.

Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, Walsh TJ, Maertens J, Patterson TF, Perfect JR, Dupont B, Wingard JR, Calandra T, Kauffman CA, Graybill JR, Baden LR, Pappas PG, Bennett JE, Kontoyiannis DP, Cordonnier C, Viviani MA, Bille J, Almyroudis NG, Wheat LJ, Graninger W, Bow EJ, Holland SM, Kullberg BJ, Dismukes WE, De Pauw BE.

Clin Infect Dis. 2008 Sep 1;47(5):674-83. doi: 10.1086/590566. Review.

Supplemental Content

Support Center